Researchers Targeted Tumor Microenvironments with Antibody
A new study has shown that the bispecific antibody OMTX305 can successfully destroy tumor-protecting fibroblasts.
Updated on Oct. 9, 2026 in Cancer
Live Poll
Should cancer research prioritize targeting the tumor microenvironment over the tumor cells themselves?
Researchers published a study in Science Advances demonstrating that the bispecific antibody OMTX305 reduces fibroblast levels in tumor tissue. The treatment targets fibroblasts surrounding tumors by directing the patient's own T cells against them.
Why it matters
The study highlights a potential new strategy for treating solid tumors by focusing on the microenvironment that shields cancer cells from immune responses. This approach could provide a novel pathway to improve the effectiveness of therapies for lung and ovarian cancers.
The study involved testing OMTX305 on freshly resected tumor slices from 15 patients. Over a three-day period, the fibroblast-occupied area within the tumor tissue decreased from 38% to 24%, with no observed binding to healthy human tissues.
The players
Oncomatryx
This biotechnology company is based in Zamudio, Spain, and focuses on developing therapies that target the tumor microenvironment.
Bosch Health Campus
This German institution leads medical research initiatives and collaborated on the study involving OMTX305.
University of Tübingen
This public research university in Germany provides clinical and academic expertise for medical innovation.
The details
Led by scientists from the Bosch Health Campus and the University of Tübingen, the research team cultured tumor slices with patient immune cells to evaluate the antibody. The treatment successfully induced tumor cell death by effectively stripping away the protective fibroblast layer.
Timeline
October 9, 2026: Study results were published in the journal Science Advances.
Three days: The duration required for the fibroblast-occupied area to decrease.
The Big Picture
This discovery extends current tumor microenvironment research initiatives by demonstrating a specific mechanism to deplete protective fibroblasts. By targeting the supportive stroma rather than the cancer cells alone, this study marks a departure from traditional drug delivery paradigms.
This research remains in the pre-clinical stage and does not yet change treatment options for current patients. Future clinical trials will determine if this antibody can effectively identify and benefit specific patient profiles with lung or ovarian cancers.
The takeaway
Targeting the protective cellular environment surrounding tumors is an evolving strategy in oncology that may eventually bypass some forms of treatment resistance. Future research will focus on translating these tissue-culture results into human clinical trials.
Further reading
Learn more about the latest research and clinical developments in Cancer.
More information
View the complete Science Advances research publication for more detailed study findings.
Live Poll
Should cancer research prioritize targeting the tumor microenvironment over the tumor cells themselves?
